The European Union's drug regulator has said that it has started reviewing US drugmaker Merck & Co Inc's experimental Covid-19 antiviral pill for adults following an application and could issue an opinion “within weeks,” reports Reuters.
The European Medicines Agency has already evaluated a substantial portion of the data during a rolling review that began in October.
Merck's pill Lagevrio has shown it can halve the chances of dying or being hospitalised for those most at risk of developing severe Covid-19 when given early in the illness.
